Slides on Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen

Learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted
William R. Short, MD, MPH, AAHIVS
Format: Microsoft PowerPoint (.ppt)
File Size: 442 KB
Released: September 30, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Commentary from Dr Yan Zhao on the latest findings from EACS 2021 highlighting the unique challenges of older people living with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 30, 2021

Expert commentary on what long-acting ART means for people with HIV, from Dr Jean-Michel Molina and Clinical Care Options (CCO)

Jean-Michel Molina, MD, PhD Released: November 30, 2021

Commentary from Dr Karine Lacombe on the potential role of an investigational 2-drug regimen of lenacapavir plus islatravir, from Clinical Care Options (CCO)

Karine Lacombe, MD, PhD Released: November 30, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue